Caribou Biosciences vs Opus Genetics
Opus Genetics is the larger business, with $14.2m of revenue in fiscal 2025 against $11.2m for Caribou Biosciences (1.3 times as much). Opus Genetics grew faster (29.1% against 11.7%). Opus Genetics kept more of each dollar of sales as profit: a net margin of -349.3% against -1327.4%. Caribou Biosciences carries less debt relative to equity (0.0% against 7.4%).
| Latest fiscal year | Caribou BiosciencesCRBU, 2025 | Opus GeneticsIRD, 2025 |
|---|---|---|
| Revenue | $11.2m | $14.2m |
| Revenue growth | 11.7% | 29.1% |
| Net income | −$148m | −$49.6m |
| Operating margin | -1329.4% | -271.9% |
| Net margin | -1327.4% | -349.3% |
| Return on equity | -79.0% | — |
| Free cash flow | −$112m | −$35.3m |
| Cash | $12.4m | $45.1m |
| Total debt | $0 | $1.1m |
| Debt to equity | 0.0% | 7.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 27 |
| Market value | $47.4m | $324m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 5 sales | 2 buys, 23 sales |